ARV-471 (PF-07850327) is being evaluated against fulvestrant in patients with ER+/HER2- advanced breast cancer who have progressed after prior endocrine therapy. The trial aims to establish ARV-471 as a superior treatment option, potentially capturing market share from existing therapies like fulvestrant. Given the increasing prevalence of advanced breast cancer and the need for effective treatments post-endocrine therapy, successful outcomes could position ARV-471 favorably in a competitive landscape dominated by CDK4/6 inhibitors and other SERDs. Diligence should focus on market access strategies and potential partnerships, especially considering the collaboration with Arvinas Estrogen Receptor, Inc.